Showing 1721-1730 of 2123 results for "".
- Anti-Inflammatory Drug Not Effective as Treatment for “Long COVID” Symptomshttps://practicalneurology.com/news/anti-inflammatory-drug-not-effective-as-treatment-for-long-covid-symptoms/2484498/Treatment with colchicine for 26 days was not shown to improve functional capacity, respiratory measures, inflammatory markers, or patient-reported outcomes in adults with the chronic condition ‘long COVID,’ according to study results published in JAMA Internal Medicine. In the article,
- Evidence Shows Telemedicine With Neurologists Is Effective For Patients and Caregivershttps://practicalneurology.com/news/evidence-shows-telemedicine-with-neurologists-is-effective-for-patients-and-caregivers/2469091/According to a review of the evidence conducted by the American Academy of Neurology (AAN) and published in the journal Neurology, seeing a neurologist by video may be as effective as an in-person visit.
- Promising Results Reported for Oral Therapy for Obstructive Sleep Apneahttps://practicalneurology.com/news/promising-results-reported-for-oral-therapy-for-obstructive-sleep-apnea/2474868/Treatment with AD109 (Apnimed, Cambridge, MA), an investigational oral therapy for obstructive sleep apnea (OSA), was found to significantly reduce the apnea-hypopnea index (AHI) at 26 weeks (P=.001), according to topline results from the phase 3 SynAIRgy clinical study (NCT05813275). AD109 treat
- Lecanemab, an Antibody to Amyloid Beta, Reduced Amyloid Levels and Cognitive Declinehttps://practicalneurology.com/news/lecanemab-an-antibody-to-amyloid-beta-reduced-amyloid-levels-and-cognitive-decline/2469653/Preliminary assessment of results clinical trials of lecanemab (BAN2401; Biogen, Cambridge, MA; Eisai, Tokyo, Japan) for potential treatment of Alzheimer disease (AD), were presented at the Alzheimer’s Association International Conference July 26-30, 2021. Lecanemab reduced brain
- Metabolic Regulator Shows Promise for Life-Saving Treatment of Thymidine Kinase Deficiency Disordershttps://practicalneurology.com/news/metabolic-regulator-shows-promise-for-life-saving-treatment-of-thymidine-kinase-deficiency-disorders/2469047/In a global phase 2 study of pyrimidine nucleoside substrate enhancement therapy (SET) (MT1621; Modis Therapeutics/Zogenix, Oakland, CA) for treating thymidine kinase 2 (TK2) deficiency all treated participants survived. Most individuals treated with SET had improved (68%) or stabilized (26%) mot
- First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer's Diseasehttps://practicalneurology.com/news/first-participant-dosed-in-phase-2-trial-of-phosphodiesterase-inhibitor-ar1001-for-alzheimers-disease/2468777/The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is being investigated for treatment of Alzheimer’s disease (AD). The 26-week double-blind placebo-controlled stu
- Individuals With Poorly Controlled Type 1 Diabetes May Have More Risk of Dementiahttps://practicalneurology.com/news/individuals-with-poorly-controlled-type-1-diabetes-may-have-more-risk-of-dementia/2469604/According to research published in Neurology, individuals with type 1 diabetes who have been to the hospital at some point for hypo- or hyperglycemia may be at 6 times more risk for developing dementia years later. The study found individuals with type 1 diabetes who visited the hospital
- Clinical Trial of Nanocrystalline Gold for Amyotrophic Lateral Sclerosis Completes Double-Blinded Phasehttps://practicalneurology.com/news/clinical-trial-of-nanocrystalline-gold-for-amyotrophic-lateral-sclerosis-completes-double-blinded-phase/2469688/All patient visits have been completed in the phase 2 study (NCT04098406) of catalytically active gold nanocrystals (Clene Nanomedicine, Salt Lake City, UT) for early-stage amyotrophic lateral scl
- Ultrasound-Guided Lumbar Puncture Not Superior to Traditional Landmark-Based Approach According to Study at AAN 2024https://practicalneurology.com/news/ultrasound-guided-lumbar-puncture-not-superior-to-traditional-landmark-based-approach-according-to-study-at-aan-2024/2470441/Ultrasound guidance did not significantly affect the outcomes of lumbar puncture (LP) performed by a single experienced practitioner in the outpatient setting. According to data from the UltraGUD LP clinical trial (NCT03815045), which were presented at the American Academy of Neurology (AAN) 2024
- Gabapentin Users Experienced Fewer Falls than Duloxetine Usershttps://practicalneurology.com/news/gabapentin-users-experienced-fewer-falls-than-duloxetine-users/2470943/Treatment with gabapentin may be associated with a reduced risk of falls compared with duloxetine, according to study results published in the Annals of Internal Medicine. Gabapentin users demonstrated significantly fewer fall-related healthcare visits compared with duloxetine users and an approx